US20230399285A1 - Illudin analogs, uses thereof, and methods for synthesizing the same - Google Patents
Illudin analogs, uses thereof, and methods for synthesizing the same Download PDFInfo
- Publication number
- US20230399285A1 US20230399285A1 US18/238,512 US202318238512A US2023399285A1 US 20230399285 A1 US20230399285 A1 US 20230399285A1 US 202318238512 A US202318238512 A US 202318238512A US 2023399285 A1 US2023399285 A1 US 2023399285A1
- Authority
- US
- United States
- Prior art keywords
- group
- cycloadduct
- cyclopentenone
- hydroxyureamethylacylfulvene
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 36
- 230000002194 synthesizing effect Effects 0.000 title claims description 10
- 229930190064 illudin Natural products 0.000 title abstract description 23
- -1 preparation methods Substances 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 40
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 claims description 20
- HLAKJNQXUARACO-UHFFFAOYSA-N acylfulvene Natural products CC1(O)C(=O)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-UHFFFAOYSA-N 0.000 claims description 17
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 claims description 15
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 125000003158 alcohol group Chemical group 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 150000008049 diazo compounds Chemical class 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 239000000543 intermediate Substances 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000003287 optical effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 229950005254 irofulven Drugs 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 239000003480 eluent Substances 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- QVMDIQLUNODCTG-UHFFFAOYSA-N (3'R)-3'r,6't-Dihydroxy-2',2',4',6'c-tetramethyl-2',3'-dihydro-spiro[cyclopropan-1,5'-inden]-7'-on Natural products CC1=C2C(O)C(C)(C)C=C2C(=O)C(C)(O)C11CC1 QVMDIQLUNODCTG-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LAPMYXLSCQDWCW-UHFFFAOYSA-N 4-(methoxymethoxy)-5-methylcyclopent-2-en-1-one Chemical compound COCOC1C=CC(C1C)=O LAPMYXLSCQDWCW-UHFFFAOYSA-N 0.000 description 7
- YBOSXQPPIAJHBR-UHFFFAOYSA-N 4-hydroxy-5-methylcyclopent-2-en-1-one Chemical compound CC1C(O)C=CC1=O YBOSXQPPIAJHBR-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- UABXUIWIFUZYQK-UHFFFAOYSA-N 1-(furan-2-yl)ethanol Chemical compound CC(O)C1=CC=CO1 UABXUIWIFUZYQK-UHFFFAOYSA-N 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- DDLLIYKVDWPHJI-RDBSUJKOSA-N Illudin S Chemical compound C12([C@@](C)(O)C(=O)C3=C[C@@](C)(CO)[C@H](O)C3=C2C)CC1 DDLLIYKVDWPHJI-RDBSUJKOSA-N 0.000 description 6
- AKYKZQWKCBEJHI-UHFFFAOYSA-N Illudin S Natural products CC1=C2C(O)C(C)(CO)C=C2C(=O)C(O)C13CC3 AKYKZQWKCBEJHI-UHFFFAOYSA-N 0.000 description 6
- DDLLIYKVDWPHJI-UHFFFAOYSA-N Lampterol Natural products CC1=C2C(O)C(C)(CO)C=C2C(=O)C(C)(O)C11CC1 DDLLIYKVDWPHJI-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 150000003509 tertiary alcohols Chemical class 0.000 description 5
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 5
- HLAKJNQXUARACO-CYBMUJFWSA-N (5's)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-CYBMUJFWSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 4
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- JIOYLBIVCRZUEQ-UHFFFAOYSA-N 1-acetylcyclopropane-1-carboxylic acid Chemical compound CC(=O)C1(C(O)=O)CC1 JIOYLBIVCRZUEQ-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QVMDIQLUNODCTG-OCCSQVGLSA-N Illudin M Chemical compound C12([C@@](C)(O)C(=O)C3=CC(C)(C)[C@H](O)C3=C2C)CC1 QVMDIQLUNODCTG-OCCSQVGLSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241001674286 Omphalotus illudens Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- AYIYPHDKKVWZKI-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;piperazine Chemical compound C1CNCCN1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO AYIYPHDKKVWZKI-LJTMIZJLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NZDXSXLYLMHYJA-UHFFFAOYSA-M 4-[(1,3-dimethylimidazol-1-ium-2-yl)diazenyl]-n,n-dimethylaniline;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=NC1=[N+](C)C=CN1C NZDXSXLYLMHYJA-UHFFFAOYSA-M 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001237902 Omphalotus Species 0.000 description 1
- 241001237912 Omphalotus nidiformis Species 0.000 description 1
- 241001247959 Omphalotus olearius Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- LDDQLRUQCUTJBB-UHFFFAOYSA-N ammonium fluoride Chemical compound [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- FOHGPRAJGVHHFX-UHFFFAOYSA-M bis(2-methylpropyl)alumanylium;hydroxide Chemical compound [OH-].CC(C)C[Al+]CC(C)C FOHGPRAJGVHHFX-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- SYBXSZMNKDOUCA-UHFFFAOYSA-J rhodium(2+);tetraacetate Chemical compound [Rh+2].[Rh+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O SYBXSZMNKDOUCA-UHFFFAOYSA-J 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JKUYRAMKJLMYLO-UHFFFAOYSA-N tert-butyl 3-oxobutanoate Chemical compound CC(=O)CC(=O)OC(C)(C)C JKUYRAMKJLMYLO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
- C07C49/573—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
- C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
- C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
- C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Definitions
- This relates to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof.
- Illudins are a family of sesquiterpenes with antitumor antibiotic properties and are traditionally produced by various mushrooms. In their isolated form, illudins show selective toxicity for myelocytic leukemia and other malignant cells. Omphalotus species like O. olearius and O. illudens (Jack o' Lantern mushrooms), and O. nidiformis (Australian ghost fungus) produce the natural forms of Illudins. Illudins are highly toxic and have little therapeutic value in their natural forms.
- FIG. 1 shows the current semi-synthetic pathway from Illudin S to hydroxymethylacylfulvene (HMAF) and (+) hydroxyureamethylacylfulvene.
- This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
- the illudin derivatives react with DNA, which blocks the transcription process, which can effectively treat cancers and inflammatory diseases.
- Another embodiment provides a synthetic pathway to acylfulvene, irofulven (6-hydroxymethylacylfulvene), UMAF and other analogs of compound I or illudin.
- the specific embodiments include derivations of enantiopure and racemic forms of acylfulvene, irofulven, and UMAF.
- the racemic and positive (+) entantiomer of UMAF are novel compounds as disclosed in the present invention.
- FIG. 1 shows a prior art current semi-synthetic pathway from Illudin S to hydroxymethyl acylfulvene (HMAF) and (+) hydroxyureamethylacylfulvene.
- FIG. 2 shows one embodiment of this invention to prepare a pivitol intermediate or tertiary alcohol.
- FIG. 3 shows another embodiment includes a method for synthesizing a compound into ( ⁇ )-acylfulvene by two exemplary strategies.
- FIG. 4 show that the (+) enantiomer is more toxic to the DU145 cell line.
- FIG. 5 show that the PC3 cell line has similarly sensitive to both enantiomeric forms of hydroxyureamethylacylfulvene
- FIG. 6 show that the (+) enantiomer is more toxic to the OVCAR3 cell line
- FIG. 7 show that the (+) enantiomer is more toxic to the SK-OV3 cell line.
- FIG. 8 show that the HCC827 cell line has similarly sensitive to both enantiomeric forms of hydroxyureamethylacylfulvene
- FIG. 9 show that the (+) enantiomer is more toxic to the H1975 cell line.
- a “patient,” “subject,” “individual,” and “host” refer to either a human or a non-human animal suffering from or suspected of suffering from a disease or disorder associated with aberrant biological or cell growth activity.
- treat and “treating” such a disease or disorder refers to ameliorating at least one symptom of the disease or disorder.
- These terms when used in connection with a condition such as a cancer, refer to one or more of impeding growth of the cancer, causing the cancer to shrink by weight or volume, extending the expected survival time of the patient, inhibiting tumor growth, reducing tumor mass, reducing size or number of metastatic lesions, inhibiting the development of new metastatic lesions, prolonging survival, prolonging progression-free survival, prolonging time to progression, and/or enhancing quality of life.
- prevention of cancer refers to a reduction in the frequency of, or delay in the onset of, symptoms of the condition or disease.
- prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.
- pharmaceutically acceptable means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- stereoisomers refers to any enantiomers, diastereomers, or geometrical isomers of the compounds of formula (I) wherever they are chiral or when they bear one or more double bond.
- the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known or employed as such in the synthesis.
- therapeutic effect refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, caused by administration of a compound or composition of the invention.
- therapeutically-effective amount means that amount of a compound or composition of the invention that is effective to treat a disease or condition caused by aberrant biological activity at a reasonable benefit/risk ratio.
- the therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of skill in the art.
- An embodiment of the present application provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
- the illudin derivatives react with DNA, which blocks the transcription process, which can effectively treat cancers and inflammatory diseases.
- One illustrative embodiment of this invention provides the compound with formula I.
- R 1 , R 2 and R 3 are independently (C1-C4) alkyl, methyl, or hydroxyl
- HMAF hydroxymethylacylfulvene
- Yet another illustrative embodiment includes ( ⁇ )-HydroxyUreaMethylAcylfulvene, (UMAF), which has the following formula III
- UMAF is the enantiomer, which exhibits at room temperature a positive optical rotation in dichloromethane or methanol.
- UMAF has a positive optical activity or may be part of a racemic mixture/mixture of UMAF structures.
- a mixture can include the following structures:
- Another embodiment provides a synthetic pathway to acylfulvene, irofulven (6-hydroxymethylacylfulvene), UMAF and other analogs of compound I or illudin.
- the specific embodiments include derivations of enantiopure and racemic forms of acylfulvene, irofulven, and UMAF.
- the racemic and positive (+) entantiomer of UMAF are novel compounds as disclosed in the present invention.
- one embodiment includes the steps of (1) converting 2-furfural using a Grignard reaction, to produce an alcohol of the below formula in which R 1 is a hydrogen atom, methyl group, alkyl group, allyl or ⁇ -methylallyl group.
- protecting groups include, but are not limited to, Silyl [trimethylsilane (TMS), tert-butyl, dimethylsilyl (TBS), acetates (Acetate (Ac), and benzoyl (Bz),] or benzyl [benzyl (Bn, para-methoxybenzyl (PMB)).
- Utilization of a carbonyl-ylide dipolar-cycloaddition between cyclopentenone 9 and diazoketone 10 provides the cycloadduct 11 which is transformed to 12 via base-mediated elimination.
- Selective alkylation of the ketone over the enone furnishes a pivitol intermediate: tertiary alcohol 13. removing the protecting group from the molecule (e.g., by base-mediated elimination).
- Selective alkylation of the ketone over the enone provides the tertiary alcohol.
- Another embodiment provides a method for synthesizing acylfulvene (3), irofulven (4) and HydroxyUreaMethylAcylfulvene, (5) from a tertiary alcohol.
- the tertiary alcohol may be a racemate or an enantiopure form, would commence with the alkylation of 2-furfural (6) with methyl Grignard, followed by a Piancatelli rearrangement to the racemic cyclopentenone ( ⁇ )-8 which would then be protected to furnish 9 (Scheme 2).
- another embodiment includes a method for synthesizing compound 13 into ( ⁇ )-acylfulvene (3) by two exemplary strategies (Scheme 3).
- a Lewis acid-mediated elimination furnishes the dienone 14, which, after reduction and elimination of the ketone moiety, produces the diol ( ⁇ )-16.
- the oxidation of compound ( ⁇ )-16 then can result in ( ⁇ )-acylfulvene (3).
- reduction of compound 13 yields alcohol 15, which after subjection to Lewis acidic conditions produces the diol ( ⁇ )-16 and ( ⁇ )-acylfulvene (3) is made in the same manner.
- ( ⁇ )-irofulven (4) and ( ⁇ )-UMAF (5) can then be made via a similar sequence described in Scheme 1.
- the disclosed transformation of 6 into acylfulvene (3), irofulven (4) and UMAF (5) may be the shortest and most efficient synthesis of these compounds to date.
- a mixture or racemic intermediate ( ⁇ )-16 can be purified via preparative chiral chromatography or other method known to those skilled in the art to produce both (+)-(16) and ( ⁇ )-16 which can be used to synthesize either enantiomer of acylfulvene (3), Irofulven (4) or UMAF (5) (Scheme 4). This represents a process for the enantioselective synthesis of these compounds.
- either enantiomer of acylfulvene (3), Irofulven (4) or UMAF (5) can also be synthesized via the known enzymatic resolution of racemic ( ⁇ )-9 to generate either ( ⁇ )-9 or ( ⁇ )-9, which can be converted to either acylfulvene (3), Irofulven (4) or UMAF (5) via the procedure described in Scheme 2 and 3 (Scheme 5).
- compositions containing a pharmaceutically acceptable carrier and any compound of Formulas (I), (II), (III) and other compounds shown above.
- compositions and compounds e.g., UMAF, having reduced toxicity and side effects (including eye-related toxicities).
- Other embodiments allow for methods for treatment taking advantage of those properties.
- “Pharmaceutically acceptable salt” refers to any salt of a compound of the invention which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use.
- Pharmaceutically acceptable salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include.
- Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesul
- Pharmaceutically acceptable salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, besylate, acetate, maleate, oxalate and the like.
- compositions of the invention comprise one or more compounds of the invention and one or more physiologically or pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof.
- Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
- materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide;
- compositions of the invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions of the invention are administered orally, intraperitoneally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- Other commonly used surfactants such as Tween, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- carriers commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried cornstarch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- compositions of this invention may be administered in the form of suppositories for rectal administration.
- suppositories for rectal administration.
- suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- compositions in a single dosage form will vary depending upon the host treated, the particular mode of administration.
- the compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- toxicity and therapeutic efficacy of compounds of the invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
- the LD 50 is the dose lethal to 50% of the population.
- the ED 50 is the dose therapeutically effective in 50% of the population.
- the dose ratio between toxic and therapeutic effects (LD50/ED50) is the therapeutic index.
- Compounds that exhibit large therapeutic indexes are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- a second therapeutic agent can be administered to mitigate the toxic side effects of a primary treatment agent.
- the dosage of such compounds may lie within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC 50 i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
- the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
- Spectral splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; sex, sextet; sept, septuplet; m, multiplet; comp, overlapping multiplets of magnetically nonequivalent protons; br, broad; and app, apparent.
- tert-butyl 3-oxobutanoate (339 g, 350 mL, 2.146 mol) was added to a vigorously stirred mixture of K 2 CO 3 (1186 g, 8.58 mol) and DMSO (3.5 L) in a flask. The mixture was stirred for 10 minutes whereupon neat 1,2-dibromoethane (806 g, 370 mL, 4.29 mol) was added and the mixture was stirred overnight. The reaction mixture was then diluted with H 2 O (2 L) and the mixture was extracted with MTBE (3 ⁇ 500 mL).
- reaction mixture was then diluted with CH 2 Cl 2 (50 mL), quenched with 10% (aq) NH 4 Cl (50 mL) and the organics were separated. The aqueous layer was extracted with CH 2 Cl 2 (50 mL) and the combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure by rotary evaporator.
- the mixture was filtered through Celite (50 g), concentrated to an oil and purified on a silica plug (350 g, elute with 1000 mL CH 2 Cl 2 ) and concentrating the eluent to recover 29.3 g of a deep red-brown oil which contained 11.23 g diazoketone (10) (49%) by NMR using mesitylene as an internal standard. The material was taken directly on to the next step.
- Cycloadduct (11) A stirring solution of diazoketone (10) (11.23 g, 73.8 mmol) and ( ⁇ )-4-(Methoxymethoxy)-5-methylcyclopent-2-en-1-one (9) (5.76 g, 36.9 mmol) in CH 2 Cl 2 was evacuated and filled with nitrogen (3 ⁇ ) before adding solid Rh 2 (OAc) 4 (42 mg, 0.095 mmol) at room temperature and stirring overnight. The reaction was then concentrated under reduced pressure and purified by flash chromatography on silica gel (column: 120 g silicycle; Eluent: gradient EtOAc 0 ⁇ 80% in hexane) to recover 10.8 g (96%) by NMR using mesitylene as an internal standard. of Cycloadduct (11) as a waxy orange solid.
- Aqueous phase was extracted with DCM (100 mL) and the combined organic extracts were washed with 20% aq. NaCl (100 mL) and dried over Na 2 SO 4 and concentrated to an oil.
- the oil was purified via silica gel column chromatography (column: 40 g silicycle; Eluent: gradient EtOAc 0 ⁇ 45% in hexane) to recover 778 mg (13.2%) of methyladduct target product as a white crystals, along with 2.23 g (39.8%) of starting material, 762 mg (12.9%) of second isomer and 833 g (13.5%) of bis methyl adduct for a total mass balance of 92.6%.
- reaction was then diluted with H 2 O (250 mL), extracted with EtOAc (2 ⁇ 150 mL) and the organic layer was washed with 5% (aq) citric acid monosodium salt (2 ⁇ 100 mL), dried over Na 2 SO 4 , concentrated to an oil and purified via silica gel column chromatography (column: 25 g silicycle; Eluent: gradient EtOAc 0 ⁇ 55% in hexane) to recover 774 mg (39%) of the dieneone product (14) as a yellowish solid.
- H 2 O (1 mL) followed by H 3 PO 4 (85% w/w in H 2 O, 0.35 mL) was added to a vigorously stirred suspension of silica (10 g) in CH 2 Cl 2 (50 mL) and the mixture was stirred at room temperature for 2 h. The solvent was then removed under reduced pressure until the silica was free-flowing.
- the crude oil from the DIBAL-H reduction was dissolved in EtOAc (200 mL) before adding H 3 PO 4 -doped hydrated silica (6.2 g) and the suspension was stirred vigorously for 3 h. The reaction was then quenched with TEA (430 ⁇ L, 312 mg, 3.08 mmol) and filtered.
- (+)-Acylfulvene (3) Diol (30 mg, 0.137 mmol) was dried azeotropically by dissolving in toluene (5 mL) and concentrating under reduced pressure before adding dry DMSO (5 mL) followed by IBX 45 wt. % (171 mg, 0.275 mmol) and the suspension was stirred at room temperature for 2 h.
- (+)-Irofulven (4) A suspension of paraformaldehyde (186 mg, 6.21 mmol as monomer) in 1M (aq) H 2 SO 4 (9 mL) was heated to 90 HC for 30 min and cooled to room temperature before adding acetone (9 mL) and a solution on (+)-Acylfulvene (3) (30 mg, 0.138 mmol) in acetone (3 mL) and the mixture was stirred for 72 h at room temperature. The reaction was then diluted with H 2 O (30 mL), extracted with CH 2 Cl 2 (3 ⁇ 15 mL) and the combined organic extracts were washed with NaHCO 3 (aq) (15 mL) then H 2 O (15 mL), water wash pH ⁇ 7.
- (+)-hydroxyureamethylacylfulvene (5) Hydroxyurea (7.5 mg, 0.098 mmol) was added to a solution of (+)-Irofulven (4) (12 mg, 0.049 mmol) in a mixture of acetone (1 mL) and 2M (aq) H 2 SO 4 (1 mL) and the mixture was stirred for 24 h at room temperature before diluting with H 2 O (15 mL) and EtOAc (15 mL), organics were separated and aqueous layer was extracted with EtOAc (2 ⁇ 10 mL). The combined organic extracts were washed with NaHCO 3 (aq) (10 mL) the brine (10 mL).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value.
Description
- This relates to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof.
- Illudins are a family of sesquiterpenes with antitumor antibiotic properties and are traditionally produced by various mushrooms. In their isolated form, illudins show selective toxicity for myelocytic leukemia and other malignant cells. Omphalotus species like O. olearius and O. illudens (Jack o' Lantern mushrooms), and O. nidiformis (Australian ghost fungus) produce the natural forms of Illudins. Illudins are highly toxic and have little therapeutic value in their natural forms.
- Methods of manufacturing Illudin analogs have generally required the production of Illudin S from liquid growth of an O. illudins cell culture.
FIG. 1 (prior art) shows the current semi-synthetic pathway from Illudin S to hydroxymethylacylfulvene (HMAF) and (+) hydroxyureamethylacylfulvene. Although O. illudins cell lines have been developed that produce a higher ratio of Illudin S to Illudin M, the production of this starting compound has been difficult in terms of expression yields, the time (e.g., >4 weeks of culture) required to begin harvesting Illudin S, contamination with Illudin M, and other complications including difficulties with reproducibility. The fermentation process can require the production, handling, and purification of large quantities of Illudin S which is highly toxic and represents a biohazard in the manufacturing facility. - Accordingly, there has been a pressing need for improved Illudins analogs and methods to synthesize the same.
- This invention provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value. The illudin derivatives react with DNA, which blocks the transcription process, which can effectively treat cancers and inflammatory diseases.
- Another embodiment provides a synthetic pathway to acylfulvene, irofulven (6-hydroxymethylacylfulvene), UMAF and other analogs of compound I or illudin. A method of synthesizing compounds of formula (I) in which R1, R2 and R3 are independently (C1-C4) alkyl, methyl, or hydroxyl. In addition, the specific embodiments include derivations of enantiopure and racemic forms of acylfulvene, irofulven, and UMAF. The racemic and positive (+) entantiomer of UMAF are novel compounds as disclosed in the present invention.
-
FIG. 1 shows a prior art current semi-synthetic pathway from Illudin S to hydroxymethyl acylfulvene (HMAF) and (+) hydroxyureamethylacylfulvene. -
FIG. 2 shows one embodiment of this invention to prepare a pivitol intermediate or tertiary alcohol. -
FIG. 3 shows another embodiment includes a method for synthesizing a compound into (±)-acylfulvene by two exemplary strategies. -
FIG. 4 show that the (+) enantiomer is more toxic to the DU145 cell line. -
FIG. 5 show that the PC3 cell line has similarly sensitive to both enantiomeric forms of hydroxyureamethylacylfulvene, -
FIG. 6 show that the (+) enantiomer is more toxic to the OVCAR3 cell line, -
FIG. 7 show that the (+) enantiomer is more toxic to the SK-OV3 cell line. -
FIG. 8 show that the HCC827 cell line has similarly sensitive to both enantiomeric forms of hydroxyureamethylacylfulvene, and -
FIG. 9 show that the (+) enantiomer is more toxic to the H1975 cell line. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
- As used herein, the terms a “patient,” “subject,” “individual,” and “host” refer to either a human or a non-human animal suffering from or suspected of suffering from a disease or disorder associated with aberrant biological or cell growth activity.
- The terms “treat” and “treating” such a disease or disorder refers to ameliorating at least one symptom of the disease or disorder. These terms, when used in connection with a condition such as a cancer, refer to one or more of impeding growth of the cancer, causing the cancer to shrink by weight or volume, extending the expected survival time of the patient, inhibiting tumor growth, reducing tumor mass, reducing size or number of metastatic lesions, inhibiting the development of new metastatic lesions, prolonging survival, prolonging progression-free survival, prolonging time to progression, and/or enhancing quality of life.
- The term “preventing” when used in relation to a condition or disease such as cancer, refers to a reduction in the frequency of, or delay in the onset of, symptoms of the condition or disease. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount.
- The term “pharmaceutically acceptable” means that, which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
- The term “stereoisomers” refers to any enantiomers, diastereomers, or geometrical isomers of the compounds of formula (I) wherever they are chiral or when they bear one or more double bond. When the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known or employed as such in the synthesis.
- The term “therapeutic effect” refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, caused by administration of a compound or composition of the invention. The phrase “therapeutically-effective amount” means that amount of a compound or composition of the invention that is effective to treat a disease or condition caused by aberrant biological activity at a reasonable benefit/risk ratio.
- The therapeutically effective amount of such substance will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of skill in the art.
- An embodiment of the present application provides illudin derivatives, intermediates, preparation methods, pharmaceutical compositions and uses thereof. Specific examples include novel synthetic routes to prepare illudin derivatives and an illudin derivative having a positive optical rotation, which has therapeutic value. The illudin derivatives react with DNA, which blocks the transcription process, which can effectively treat cancers and inflammatory diseases.
- One illustrative embodiment of this invention provides the compound with formula I.
- The R1, R2 and R3 are independently (C1-C4) alkyl, methyl, or hydroxyl
- Another illustrative embodiment includes hydroxymethylacylfulvene (HMAF, Irofulven), which has the following formula II
- Yet another illustrative embodiment includes (−)-HydroxyUreaMethylAcylfulvene, (UMAF), which has the following formula III
- One illustrative embodiment is characterized in that UMAF is the enantiomer, which exhibits at room temperature a positive optical rotation in dichloromethane or methanol. UMAF has a positive optical activity or may be part of a racemic mixture/mixture of UMAF structures. A mixture can include the following structures:
- This application provides methods of synthesizing compounds of formula (IV):
- Another embodiment provides a synthetic pathway to acylfulvene, irofulven (6-hydroxymethylacylfulvene), UMAF and other analogs of compound I or illudin. A method of synthesizing compounds of formula (I) in which R1, R2 and R3 are independently (C1-C4) alkyl, methyl, or hydroxyl. In addition, the specific embodiments include derivations of enantiopure and racemic forms of acylfulvene, irofulven, and UMAF. The racemic and positive (+) entantiomer of UMAF are novel compounds as disclosed in the present invention.
- Referring now to
FIG. 2 , one embodiment includes the steps of (1) converting 2-furfural using a Grignard reaction, to produce an alcohol of the below formula in which R1 is a hydrogen atom, methyl group, alkyl group, allyl or α-methylallyl group. - (2) Piancatelli rearrangement to the racemic cyclopentenone, and (3) protecting the alcohol group to furnish 9. In producing alcohols from carbonyl compounds by the Grignard reaction, a common practice is to prepare a Grignard reagent and then allow it to react with carbonyl compounds. The selection of appropriate protecting groups, can be readily determined by one skilled in the art—exemplary protecting groups include, but are not limited to, Silyl [trimethylsilane (TMS), tert-butyl, dimethylsilyl (TBS), acetates (Acetate (Ac), and benzoyl (Bz),] or benzyl [benzyl (Bn, para-methoxybenzyl (PMB)). Utilization of a carbonyl-ylide dipolar-cycloaddition between
cyclopentenone 9 and diazoketone 10 provides the cycloadduct 11 which is transformed to 12 via base-mediated elimination. Selective alkylation of the ketone over the enone furnishes a pivitol intermediate:tertiary alcohol 13. removing the protecting group from the molecule (e.g., by base-mediated elimination). Selective alkylation of the ketone over the enone provides the tertiary alcohol. - Another embodiment provides a method for synthesizing acylfulvene (3), irofulven (4) and HydroxyUreaMethylAcylfulvene, (5) from a tertiary alcohol. The tertiary alcohol may be a racemate or an enantiopure form, would commence with the alkylation of 2-furfural (6) with methyl Grignard, followed by a Piancatelli rearrangement to the racemic cyclopentenone (±)-8 which would then be protected to furnish 9 (Scheme 2).
- Referring now to
FIG. 3 , another embodiment includes a method for synthesizingcompound 13 into (±)-acylfulvene (3) by two exemplary strategies (Scheme 3). In the one exemplary method, a Lewis acid-mediated elimination furnishes thedienone 14, which, after reduction and elimination of the ketone moiety, produces the diol (±)-16. The oxidation of compound (±)-16 then can result in (±)-acylfulvene (3). In another exemplary method, reduction ofcompound 13 yieldsalcohol 15, which after subjection to Lewis acidic conditions produces the diol (±)-16 and (±)-acylfulvene (3) is made in the same manner. In another example, (±)-irofulven (4) and (±)-UMAF (5) can then be made via a similar sequence described inScheme 1. The disclosed transformation of 6 into acylfulvene (3), irofulven (4) and UMAF (5) may be the shortest and most efficient synthesis of these compounds to date. - If enantiopure acylfulvene (3), irofulven (4) or UMAF (5) are desired, a mixture or racemic intermediate (±)-16 can be purified via preparative chiral chromatography or other method known to those skilled in the art to produce both (+)-(16) and (−)-16 which can be used to synthesize either enantiomer of acylfulvene (3), Irofulven (4) or UMAF (5) (Scheme 4). This represents a process for the enantioselective synthesis of these compounds.
- As shown below, either enantiomer of acylfulvene (3), Irofulven (4) or UMAF (5) can also be synthesized via the known enzymatic resolution of racemic (±)-9 to generate either (±)-9 or (−)-9, which can be converted to either acylfulvene (3), Irofulven (4) or UMAF (5) via the procedure described in
Scheme 2 and 3 (Scheme 5).1 - Specific embodiments also feature pharmaceutical compositions containing a pharmaceutically acceptable carrier and any compound of Formulas (I), (II), (III) and other compounds shown above.
- Specific embodiments also feature compositions and compounds, e.g., UMAF, having reduced toxicity and side effects (including eye-related toxicities). Other embodiments allow for methods for treatment taking advantage of those properties.
- Pharmaceutically acceptable salts of these compounds are also contemplated for the uses described herein. “Pharmaceutically acceptable salt” refers to any salt of a compound of the invention which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Pharmaceutically acceptable salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include. Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic, glucoheptonic, 3-phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid and the like acids; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, ammonia or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like. Pharmaceutically acceptable salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, besylate, acetate, maleate, oxalate and the like.
- Pharmaceutical compositions of the invention comprise one or more compounds of the invention and one or more physiologically or pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof. Each carrier must be “acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
- The compositions of the invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the compositions of the invention are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tween, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- The pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
- The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. The compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- In terms of dosage, toxicity and therapeutic efficacy of compounds of the invention, including pharmaceutically acceptable salts and deuterated variants, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The LD50 is the dose lethal to 50% of the population. The ED50 is the dose therapeutically effective in 50% of the population. The dose ratio between toxic and therapeutic effects (LD50/ED50) is the therapeutic index. Compounds that exhibit large therapeutic indexes are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. Alternatively, a second therapeutic agent can be administered to mitigate the toxic side effects of a primary treatment agent.
- Data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds may lie within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
- In the following examples, the following abbreviations are used therein.
-
- AcOH Acetic acid
- DIBAL-H Diisobutylaluminium hydroxide
- DIPEA diisopropylethylamine
- DMSO Dimethylsulfoxide
- IBX 2-iodoxybenzoic acid
- L Liter
- M Molar
- MeOAc Methyl acetate
- MeOH Methanol
- Mmol millimole
- MTBE Methy tert-butyl ether
- NMR Nuclear Magnetic Resonance
- TFA Trifluoroacetic acid
- THE Tetrahydrofuran
- TMS tetramethylsilane
- TMSOTf trimethylsilyl trifluoromethanesulfonate
- Unless otherwise noted, solvents and reagents were used without purification. CH2Cl2 and MeCN were stored over 4 Å molecular sieves. Volatile solvents were removed under reduced pressure using a Buchi rotary evaporator. Thin layer chromatography (TLC) was performed on glass-backed precoated silica gel plates (0.25 mm thick with 60 F254) and were visualized using one or more of the following manners: UV light (254 nm), staining with I2 impregnated silica, KMnO4 or Ceric Ammonium Molybdate (CAM). Flash chromatography was performed using the Biotage Isolera One using pre-loaded Silicycle 25 g high performance (14-40 μM) columns. 1H nuclear magnetic resonance (NMR) spectra were obtained at 400 MHz as indicated as solutions in CDCl3 with 0.05% v/v tetramethylsilane (TMS) unless indicated otherwise. 13C-NMR were obtained at 100 MHz as shown in the indicated deuterated solvent. Chemical shifts are reported in parts per million (ppm, δ), and referenced to TMS, and coupling constants are reported in Hertz (Hz). Spectral splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; sex, sextet; sept, septuplet; m, multiplet; comp, overlapping multiplets of magnetically nonequivalent protons; br, broad; and app, apparent.
- 1-acetylcyclopropanecarboxylic acid. tert-butyl 3-oxobutanoate (339 g, 350 mL, 2.146 mol) was added to a vigorously stirred mixture of K2CO3 (1186 g, 8.58 mol) and DMSO (3.5 L) in a flask. The mixture was stirred for 10 minutes whereupon neat 1,2-dibromoethane (806 g, 370 mL, 4.29 mol) was added and the mixture was stirred overnight. The reaction mixture was then diluted with H2O (2 L) and the mixture was extracted with MTBE (3×500 mL). The combined organic fractions were washed with 10% brine solution (4×200 mL) and the organic layer was dried over Na2SO4 and concentrated to an oil under reduced pressure. Neat TFA (486 g, 328 mL, 4.29 mol) was added to the oil and the mixture was stirred at room temperature overnight. The TFA was removed under reduced pressure and an aqueous solution of 20% (w/w) NaOH was added until the pH of the aqueous layer was <11. The mixture was then washed with MTBE (3×200 mL) and the aqueous layer was pH adjusted to >2 with an aqueous solution of 20% (w/w) H2SO4 and the mixture was extracted with CH2Cl2 (3×200 mL) and the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to recover 182 g (66%) of crude 1-acetylcyclopropanecarboxylic acid as an orange oil.
- 1-(furan-2-yl)ethan-1-ol. (7) A three neck round bottom flask (22 L) was washed with anhydrous THF (100 mL), evacuated and filled with nitrogen (3×). The flask was then charged with THF (1500 mL) and furfural (600.0 g, 547.2 mL, 6.244 mol) and the solution was cooled to 0° C. with an ice bath and kept under a nitrogen atmosphere. A solution of methylmagnesium chloride (2289 mL, 3 M, 6.838 mol) in THF was added slowly dropwise over ˜180 min using a cannula using nitrogen pressure, carefully maintaining a reaction temperature less than 10° C. The mixture was allowed to cool to 0° C. and stirred for an additional 30 min before carefully quenching with 1N aq. HCl (1000 mL) with vigorous stirring, during which copious amounts of solids formed and the reaction mixture solidified. Water (2000 mL) was then added and the solids were agitated mechanically to break up the solids before adding an additional 1N aq. HCl (5000 mL) while carefully maintaining an internal temperature ≤10° C. The mixture was extracted with MTBE (3×1500 mL) and the organics were combined, washed with water (1000 mL), brine (1500 mL) then dried over sodium sulfate. The organic layer was then concentrated under reduced pressure by rotary evaporator to recover 678 g (96%) of crude 1-(furan-2-yl)ethan-1-ol as a ruby red liquid, which was taken on directly to the next step.
- (±)-4-hydroxy-5-methylcyclopent-2-en-1-one. (8) A 2000 mL round bottom flask equipped with a reflux condenser and magnetic stir bar was charged with deionized water (1600 mL) and 1-(2-furyl)ethanol (7) (130 g, 1159 mmol). The reaction mixture was purged with nitrogen and the mixture was brought to reflux and was heated for 120 min with vigorous stirring. The reaction mixture was then allowed to cool to ambient temperature and the aqueous solution was decanted from the brown oily resin. The aqueous layer was then washed with a mixture of MTBE and hexanes (1:1, 3×250 mL) and the organic extracts were discarded. Sodium chloride (250 g) was then added to the aqueous solution and extracted with EtOAc (3×250 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure on a rotary evaporator to recover 8.0 g (6%) of (±)-4-hydroxy-5-methylcyclopent-2-en-1-one (8) as a pale yellow oil.
- (±)-4-(Methoxymethoxy)-5-methylcyclopent-2-en-1-one. (9) A flask was charged with (±)-4-hydroxy-5-methylcyclopent-2-en-1-one (8) (1.5 g, 13.38 mmol) CH2Cl2 (80 mL), and diisopropylethylamine (DIPEA) (5.19, 6.99 mL g, 40.14 mmol) and the mixture was purged with nitrogen and cooled to 0° C. with an ice bath. Chloromethyl methyl ether (3.14 M in MeOAc; 8.51 mL) was added dropwise via syringe over 20 min. The reaction was stirred for an additional hour at 0° C. before being allowed to slowly warm up to ambient temperature and stirring overnight. The reaction mixture was then diluted with CH2Cl2 (50 mL), quenched with 10% (aq) NH4Cl (50 mL) and the organics were separated. The aqueous layer was extracted with CH2Cl2 (50 mL) and the combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure by rotary evaporator. The crude residue was purified by flash chromatography on silica gel (column: 40 g silicycle; Eluent: gradient CH2Cl2 0→100% in hexane) to recover 10.5 g (84%) of (±)-4-(Methoxymethoxy)-5-methylcyclopent-2-en-1-one (9) as a pale yellow oil.
- Diazoketone. (10) Oxalyl chloride (39.6 g, 26.4 mL, 312 mmol) was added to a solution of 1-acetylcyclopropanecarboxylic acid (20 g, 156 mmol) and DMF (110 mg, 0.12 mL, 1.5 mmol) in CH2Cl2 (200 mL) at room temperature and stirred for two hours. The reaction mixture was concentrated to an oil under reduced pressure and dissolved in anhydrous CH2Cl2 (300 mL) and cooled to −78° C. (dry ice/acetone bath). Neat 2,6-lutidine (19.3 g, 21.0 mL, 180 mmol) was added, followed by a solution of TMSCHN2 (2.0 M, 200 mL, 300 mmol) in hexanes. The cooling bath was removed and the mixture was allowed to warm to room temperature and stir overnight. The mixture was concentrated to an oil under reduced pressure before adding MTBE (200 mL) and storing in the fridge for 30 min. The mixture was filtered through Celite (50 g), concentrated to an oil and purified on a silica plug (350 g, elute with 1000 mL CH2Cl2) and concentrating the eluent to recover 29.3 g of a deep red-brown oil which contained 11.23 g diazoketone (10) (49%) by NMR using mesitylene as an internal standard. The material was taken directly on to the next step.
- Cycloadduct. (11) A stirring solution of diazoketone (10) (11.23 g, 73.8 mmol) and (±)-4-(Methoxymethoxy)-5-methylcyclopent-2-en-1-one (9) (5.76 g, 36.9 mmol) in CH2Cl2 was evacuated and filled with nitrogen (3×) before adding solid Rh2(OAc)4 (42 mg, 0.095 mmol) at room temperature and stirring overnight. The reaction was then concentrated under reduced pressure and purified by flash chromatography on silica gel (column: 120 g silicycle; Eluent:
gradient EtOAc 0→80% in hexane) to recover 10.8 g (96%) by NMR using mesitylene as an internal standard. of Cycloadduct (11) as a waxy orange solid. - 1H-NMR (400 MHz) δ 4.96 (s, 1H), 4.80 (d, J=7.2 Hz, 1H), 4.74 (d, J=7.2 Hz, 1H), 3.96 (dd, J=8.0, 11.2 Hz, 1H), 3.45 (s, 3H), 2.93 (t, J=7.6 Hz, 1H), 2.67 (d, J=6.8 Hz, 1H), 2.59 (dq, J=6.4, 11.6 Hz, 1H), 1.30 (ddd, J=4.0, 6.8, 9.6 Hz, 1H), 1.20 (s, 3H). 1.16 (ddd, J=4.0, 6.4, 8.4 Hz, 1H). 1.12 (s, 3H), 1.07 (ddd, J=4.4, 7.6, 9.6 Hz, 1H), 0.73 (ddd, J=4.0, 7.2, 9.6 Hz, 1H); 13C-NMR (100 MHz) δ 212.8, 211.8, 96.2, 87.4, 81.5, 79.9, 59.5, 50.2, 44.1, 39.0, 14.2, 13.8, 12.4, 11.2.
- NMR assignments: 1H-NMR (400 MHz) δ 4.96 (C9-H), 4.80 (C7-H), 4.74 (C7-H), 3.96 (C4-H), 3.45 (C8-H), 2.93 (C3-H), 2.67 (C2-H), 2.59 (C5-H), 1.30 (C14 or C15-H), 1.20 (C13-H). 1.16 (C14 or C15-H). 1.12 (C6-H), 1.07 (C14 or C15-H), 0.73 (C14 or C15-H); 13C-NMR (100 MHz) δ 212.8 (C1), 211.8 (C10), 96.2 (C7), 87.4 (C12), 81.5 (C9), 79.9 (C4), 59.5 (C2), 50.2 (C8, C5), 44.1 (C3), 39.0 (C11), 14.2 (C14 or C15), 13.8 (C13), 12.4 (C14 or C15), 11.2 (C6).
- Methyladduct. Starting material (11) (5.6 g, 19.97 mmol) was dissolved in dry THF (80 mL) and cooled to −78° C. with a dry ice/acetone bath. The solution was put under vacuum and back-filled with nitrogen (2 times), whereupon a solution of MeMgCl (10 mL, 3 M in THF, 30 mmol; 1.5 eq) was added dropwise and the reaction was stirred at −78° C. for 3.5 h before quenching with acetic acid (1.3 mL). The reaction was warmed to room temperature, diluted with DCM (350 mL) and water (250 mL). The resulting mixture was separated. Aqueous phase was extracted with DCM (100 mL) and the combined organic extracts were washed with 20% aq. NaCl (100 mL) and dried over Na2SO4 and concentrated to an oil. The oil was purified via silica gel column chromatography (column: 40 g silicycle; Eluent:
gradient EtOAc 0→45% in hexane) to recover 778 mg (13.2%) of methyladduct target product as a white crystals, along with 2.23 g (39.8%) of starting material, 762 mg (12.9%) of second isomer and 833 g (13.5%) of bis methyl adduct for a total mass balance of 92.6%. - Cyclopentenone. (13) Potassium carbonate (704 mg, 5.09 mmol; 1.0 eq) was added to a solution of starting material (1.50 g, 5.09 mmol) in MeOH (60 mL) and the mixture was stirred at room temperature for 2 h before quenching with 10% aq. NH4Cl (10 mL) and diluted with EtOAc 300 mL. The resulting mixture was washed with 20
% NaCl 100 mL. Organic layer was separated and washed with 20% NaCl (50 mL). The organic extract was dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 25 g silicycle; Eluent:gradient EtOAc 0→65% in hexane) to recover 974 mg (82%) of alkene Cyclopentenone (13) as a pale yellow crystals. - Dieneone. (14) Neat TMSOTf (7.72 mL, 9.48 g, 42.68 mmol) was added to a solution of bicycle (13) (2.0 g, 8.54 mmol) and 2,6-lutidine (7.46 mL, 6.86 g, 64.05 mmol) in dry CH2Cl2 (100 mL) at 0° C. and the solution was stirred for 4 hours under nitrogen atmosphere, whereupon the reaction was quenched with MeOH (4 mL) and the reaction mixture was concentrated to a red-orange oil under reduced pressure. The crude oil was suspended in MeOH (50 mL) and NH4F (6.32 g, 170.8 mmol) and AcOH (8.55 mL, 8.97 g, 149.45 mmol) was added and the suspension was stirred at room temperature overnight. The reaction was then diluted with H2O (250 mL), extracted with EtOAc (2×150 mL) and the organic layer was washed with 5% (aq) citric acid monosodium salt (2×100 mL), dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 25 g silicycle; Eluent:
gradient EtOAc 0→55% in hexane) to recover 774 mg (39%) of the dieneone product (14) as a yellowish solid. - Diol. (16) A solution of dienone (14) (770 mg, 3.28 mmol) in dry CH2Cl2 (50 mL) was cooled to −78° C. with a dry ice/acetone bath before adding a solution of DIBAL-H (13.69 mL, 1.2 M in toluene, 16.43 mmol) in hexanes. The solution was stirred for 0.5 hours, whereupon the reaction was quenched with MeOH (4 mL) and the reaction mixture was concentrated to an oil under reduced pressure. In a separate flask, H2O (1 mL) followed by H3PO4 (85% w/w in H2O, 0.35 mL) was added to a vigorously stirred suspension of silica (10 g) in CH2Cl2 (50 mL) and the mixture was stirred at room temperature for 2 h. The solvent was then removed under reduced pressure until the silica was free-flowing. The crude oil from the DIBAL-H reduction was dissolved in EtOAc (200 mL) before adding H3PO4-doped hydrated silica (6.2 g) and the suspension was stirred vigorously for 3 h. The reaction was then quenched with TEA (430 μL, 312 mg, 3.08 mmol) and filtered. The resulting solution was concentrated to an oil and purified via silica gel column chromatography (column: 4 g silicycle; Eluent:
gradient EtOAc 0→50% in hexane) to recover 83 mg (12%) of compound diol (16) as a yellow solid. - (−)-Acylfulvene. (3) Diol (16) (38 mg, 0.174 mmol) was dried azeotropically by dissolving in toluene (5 mL) and concentrating under reduced pressure before adding dry DMSO (6 mL) followed by IBX 45 wt. % (216 mg, 0.348 mmol) and the suspension was stirred at room temperature for 2 h. The mixture was then diluted with H2O (15 mL), extracted with EtOAc (2×10 mL), dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent:
gradient EtOAc 0→50% in hexane) to recover 37 mg (98%) of (−)-Acylfulvene (3) as a yellow gum. - 1H-NMR (400 MHz) δ 7.16 (d, J=0.8 Hz, 1H), 6.43 (quint, J=1.6 Hz, 1H), 3.93 (bs, 1H), 2.15 (d, J=1.2 Hz, 3H), 2.00 (s, 3H), 1.52 (ddd, J=4.0, 6.4, 9.6 Hz, 1H), 1.38 (s, 3H), 1.29 (ddd, J=4.8, 6.4, 9.6 Hz, 1H), 1.07 (ddd, J=5.2, 7.2, 9.6 Hz, 1H), 0.71 (ddd, J=4.0, 7.2, 9.6 Hz, 1H).
- NMR assignments: 1H-NMR (400 MHz) δ 7.16 (C4-H), 6.43 (C1-H), 3.93 (O—H), 2.15 (C6-H), 2.00 (C11-H), 1.52 (C12 or C13-H), 1.38 (C14-H), 1.29 (C12 or C13-H), 1.07 (C12 or C13-H), 0.71 (C12 or C13-H).
- (+)-Acylfulvene. (3) Diol (30 mg, 0.137 mmol) was dried azeotropically by dissolving in toluene (5 mL) and concentrating under reduced pressure before adding dry DMSO (5 mL) followed by IBX 45 wt. % (171 mg, 0.275 mmol) and the suspension was stirred at room temperature for 2 h. The mixture was then diluted with H2O (15 mL), extracted with EtOAc (2×10 mL), dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent:
gradient EtOAc 0→50% in hexane) to recover 30 mg (100%) of (+)-Acylfulvene as a yellow gum. - 1H-NMR (400 MHz) δ 7.16 (d, J=0.8 Hz, 1H), 6.43 (quint, J=1.6 Hz, 1H), 3.93 (bs, 1H), 2.15 (d, J=1.2 Hz, 3H), 2.00 (s, 3H), 1.52 (ddd, J=4.0, 6.4, 9.6 Hz, 1H), 1.38 (s, 3H), 1.29 (ddd, J=4.8, 6.4, 9.6 Hz, 1H), 1.07 (ddd, J=5.2, 7.2, 9.6 Hz, 1H), 0.71 (ddd, J=4.0, 7.2, 9.6 Hz, 1H).
- (−)-Irofulven. (4) A suspension of paraformaldehyde (231 mg, 7.7 mmol as monomer) in 2M (aq) H2SO4 (4 mL) was heated to 90° C. for 30 min and cooled to room temperature before adding acetone (4 mL) and a solution of (−)-Acylfulvene (3) (37 mg, 0.171 mmol) in acetone (1 mL) and the mixture was stirred for 48 h at room temperature. The reaction was then diluted with H2O (25 mL), extracted with CH2Cl2 (3×15 mL), and the combined organic extracts were washed with NaHCO3 (aq) (15 mL) then H2O (15 mL), water wash pH ˜7. The organic extracts were then dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent:
gradient EtOAc 0→65% in hexane) to recover 24.6 mg (58%) of (−)-Irofulven (4) as a yellow gum and 8.6 mg (23%) of recovered (−)-Acylfulvene. - 1H-NMR (400 MHz) δ 7.09 (s, 1H), 4.67 (d, J=12.4 Hz, 1H), 4.63 (d, J=12.4 Hz, 1H), 3.90 (bs, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 1.49 (ddd, J=4.0, 6.0, 9.6 Hz, 1H), 1.38 (s, 3H), 1.36 (ddd, J=5.2, 6.4, 9.6 Hz, 1H), 1.08 (ddd, J=4.8, 7.2, 9.6 Hz, 1H), 0.72 (ddd, J=4.0, 7.6, 10.0 Hz, 1H).
- NMR assignments: 1H-NMR (400 MHz) δ 7.09 (C4-H), 4.67 (C15-H), 4.63 (C15-H), 3.90 (O—H), 2.19 (C6-H), 2.15 (C11-H), 1.49 (C12 or C13-H), 1.38 (C14-H), 1.36 (C12 or C13-H), 1.08 (C12 or C13-H), 0.72 (C12 or C13-H).
- (+)-Irofulven. (4) A suspension of paraformaldehyde (186 mg, 6.21 mmol as monomer) in 1M (aq) H2SO4 (9 mL) was heated to 90 HC for 30 min and cooled to room temperature before adding acetone (9 mL) and a solution on (+)-Acylfulvene (3) (30 mg, 0.138 mmol) in acetone (3 mL) and the mixture was stirred for 72 h at room temperature. The reaction was then diluted with H2O (30 mL), extracted with CH2Cl2 (3×15 mL) and the combined organic extracts were washed with NaHCO3 (aq) (15 mL) then H2O (15 mL), water wash pH ˜7. The organic extracts were then dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent: gradient EtOAc 0-65% in hexane) to recover 12.7 mg (37%) of (+)-Irofulven as a yellow gum and 12.4 mg (41%) of recovered (+)-Acylfulvene (3).
- 1H-NMR (400 MHz) δ 7.09 (s, 1H), 4.67 (d, J=12.4 Hz, 1H), 4.63 (d, J=12.4 Hz, 1H), 3.90 (bs, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 1.49 (ddd, J=4.0, 6.0, 9.6 Hz, 1H), 1.38 (s, 3H), 1.36 (ddd, J=5.2, 6.4, 9.6 Hz, 1H), 1.08 (ddd, J=4.8, 7.2, 9.6 Hz, 1H), 0.72 (ddd, J=4.0, 7.6, 10.0 Hz, 1H).
- NMR assignments: 1H-NMR (400 MHz) δ 7.09 (C4-H), 4.67 (C15-H), 4.63 (C15-H), 3.90 (O—H), 2.19 (C6-H), 2.15 (C11-H), 1.49 (C12 or C13-H), 1.38 (C14-H), 1.36 (C12 or C13-H), 1.08 (C12 or C13-H), 0.72 (C12 or C13-H).
- (−)-hydroxyureamethylacylfulvene. (5) Hydroxyurea (37 mg, 0.487 mmol) was added to a solution of (−)-Irofulven (4) (24 mg, 0.097 mmol) in a mixture of acetone (1.5 mL) and 2M (aq) H2SO4 (1.5 mL) and the mixture was stirred for 24 h at room temperature before diluting with H2O (15 mL) and EtOAc (15 mL), organics were separated and aqueous layer was extracted with EtOAc (2×10 mL). The combined organic extracts were washed with 5% NaHCO3 (aq) (10 mL) the brine (10 mL). The organic extracts were then dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent: gradient EtOAc 10→95% in hexane) to recover 18.9 mg (61%) of (−)-LP-184 (5) as a yellow-orange solid.
- 1H-NMR (400 MHz) δ 7.03 (s, 1H), 6.86 (s, 1H), 5.37 (bs, 2H), 4.80 (d, J=14.8 Hz, 1H), 4.52 (d, J=14.5 Hz, 1H), 3.84 (bs, 1H), 2.17 (s, 3H), 2.08 (s, 3H), 1.47 (ddd, J=4.0, 6.4, 10.0 Hz, 1H), 1.35 (ddd, J=5.2, 6.4, 9.6 Hz, 1H), 1.35 (s, 3H), 1.34 (ddd, J=5.2, 7.6, 9.6 Hz, 1H), 0.68 (ddd, J=4.0, 7.6, 10.0 Hz, 1H).
- (+)-hydroxyureamethylacylfulvene. (5) Hydroxyurea (7.5 mg, 0.098 mmol) was added to a solution of (+)-Irofulven (4) (12 mg, 0.049 mmol) in a mixture of acetone (1 mL) and 2M (aq) H2SO4 (1 mL) and the mixture was stirred for 24 h at room temperature before diluting with H2O (15 mL) and EtOAc (15 mL), organics were separated and aqueous layer was extracted with EtOAc (2×10 mL). The combined organic extracts were washed with NaHCO3 (aq) (10 mL) the brine (10 mL). The organic extracts were then dried over Na2SO4, concentrated to an oil and purified via silica gel column chromatography (column: 12 g silicycle; Eluent: gradient EtOAc 10→95% in hexane) to recover 6.6 mg (44%) of (+)-LP-184 (5) as a yellow solid and 3.0 mg (25%) of recovered (+)-Irofulven (4).
- 1H-NMR (400 MHz) δ 7.03 (s, 1H), 6.86 (s, 1H), 5.37 (bs, 2H), 4.80 (d, J=14.8 Hz, 1H), 4.52 (d, J=14.5 Hz, 1H), 3.84 (bs, 1H), 2.17 (s, 3H), 2.08 (s, 3H), 1.47 (ddd, J=4.0, 6.4, 10.0 Hz, 1H), 1.35 (ddd, J=5.2, 6.4, 9.6 Hz, 1H), 1.35 (s, 3H), 1.34 (ddd, J=5.2, 7.6, 9.6 Hz, 1H), 0.68 (ddd, J=4.0, 7.6, 10.0 Hz, 1H).
- Cytotoxicity. The growth-inhibition activities of both purified UMAF (also referred to as UMAF in this example) optical enantiomers were studied in a standard 96-well cell-based assay using representative cell lines from prostate, ovarian, and lung cancers. The concentrations that cause a 50% inhibition of cell growth (GI50) were determined using a luminescent vital assay reagent (CellTiter-Glo®, Promega Corporation). The growth inhibition curves as a function of UMAF concentration are shown from a representative assay.
FIGS. 4, 6, 7, and 9 show that the (+) enantiomer is more toxic to DU145, OVCAR3, SK-OV3, and H1975 cell lines, respectively.FIGS. 5 and 8 show that the PC3 and HCC827 cell lines are similarly sensitive to both enantiomeric forms of the compound. The GI50 concentrations of the two forms for the six cell lines are shown below. -
Activity of UMAF on cancer cell lines* Prostate Ovarian Lung DU145 PC3 OVCAR-3 SK-OV3 HCC827 H1975 (+)-UMAF 34.8 1,120 254 554 897 287 (−)-UMAF 506 824 1,820 2,400 1,640 6,320 *Nanomolar concentrations of UMAF that inhibits 50% cell growth in a 3-day assay
Claims (15)
1. A process for synthesizing compounds having the formula (III):
wherein Ri, R2 and R3 are independently (C1-C4) alkyl, methyl, or hydroxyl, comprising the steps of
selecting a cyclopentenone having an alcohol group;
protecting the alcohol group;
reacting the protected cyclopentenone with a diazoketone to form a cycloadduct; and reducing the cycloadduct.
2. The method according to claim 1 , wherein the cyclopentenone of step a is selected from the group consisting of substituted cyclopentenones.
3. The method according to claim 1 , wherein the cleaving of the oxy group is achieved through the use of a suitable acid or base.
4. The process according to claim 1 , wherein the diazoketone is derived from a diazo compound and a ketone.
5. The process of claim 1 , wherein R1, R2, and R3 are each independently selected from (C1-C4) alkyl groups.
6. The process of claim 1 , further comprising oxidizing the cleaved cycloadduct to obtain hydroxyureamethylacylfulvene (+).
7. The method according to claim 6 , further comprising isolating hydroxyureamethylacylfulvene (+) after step g) using standard purification techniques.
9. A method of synthesizing hydroxyureamethylacylfulvene (+) comprising the steps of:
a) selecting a cyclopentenone having an alcohol group;
b) protecting the alcohol group of the selected cyclopentenone;
c) reacting the protected cyclopentenone with a diazoketone to form a cycloadduct;
d) Reducing the cycloadduct obtained in step c;
e) Alkylating a ketone group of the reduced cycloadduct;
f) Cleaving an oxy group of the alkylated cycloadduct; and
g) Oxidizing the cleaved cycloadduct to obtain hydroxyureamethylacylfulvene (+).
10. The method according to claim 9 , wherein the cyclopentenone of step a is selected from the group consisting of substituted and unsubstituted cyclopentenones.
11. The method according to claim 9 , wherein the protecting group used in step b is selected from the group consisting of acetyl, benzyl, tert-butyldimethylsilyl (TBDMS), and tert-butoxy carbonyl groups.
12. The method according to claim 9 , wherein the cleaving of the oxy group in step f is achieved through the use of a suitable reagent, such as an acid or base.
13. The method according to claim 9 , wherein the alkylating agent used in step 5 is selected from the group consisting of alkyl halides, alkyl sulfonates, and alkyl tosylates.
14. The method according to claim 9 , wherein the alkylating agent of step e) is an alkyl halide.
15. The method according to claim 9 , further comprising isolating hydroxyureamethylacylfulvene (+) after step g by standard purification techniques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/238,512 US20230399285A1 (en) | 2018-09-04 | 2023-08-27 | Illudin analogs, uses thereof, and methods for synthesizing the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862726914P | 2018-09-04 | 2018-09-04 | |
PCT/US2019/049555 WO2020051222A1 (en) | 2018-09-04 | 2019-09-04 | Illudin analogs, uses thereof, and methods for synthesizing the same |
US17/192,838 US11739043B2 (en) | 2018-09-04 | 2021-03-04 | Illudin analogs, uses thereof, and methods for synthesizing the same |
US18/238,512 US20230399285A1 (en) | 2018-09-04 | 2023-08-27 | Illudin analogs, uses thereof, and methods for synthesizing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/192,838 Continuation US11739043B2 (en) | 2018-09-04 | 2021-03-04 | Illudin analogs, uses thereof, and methods for synthesizing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230399285A1 true US20230399285A1 (en) | 2023-12-14 |
Family
ID=69722656
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/192,838 Active US11739043B2 (en) | 2018-09-04 | 2021-03-04 | Illudin analogs, uses thereof, and methods for synthesizing the same |
US18/238,512 Pending US20230399285A1 (en) | 2018-09-04 | 2023-08-27 | Illudin analogs, uses thereof, and methods for synthesizing the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/192,838 Active US11739043B2 (en) | 2018-09-04 | 2021-03-04 | Illudin analogs, uses thereof, and methods for synthesizing the same |
Country Status (10)
Country | Link |
---|---|
US (2) | US11739043B2 (en) |
EP (1) | EP3846791A4 (en) |
JP (1) | JP7489966B2 (en) |
KR (1) | KR20210087435A (en) |
CN (1) | CN112804995A (en) |
AU (1) | AU2019335222A1 (en) |
BR (1) | BR112021006710A2 (en) |
CA (1) | CA3111772A1 (en) |
MX (1) | MX2021002529A (en) |
WO (1) | WO2020051222A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11135182B2 (en) | 2014-04-10 | 2021-10-05 | Af Chemicals, Llc | Affinity medicant conjugates |
CN111269257A (en) * | 2020-03-16 | 2020-06-12 | 福建省微生物研究所 | Preparation method and application of Marizonib key intermediate |
WO2022147072A1 (en) * | 2020-12-29 | 2022-07-07 | Lantern Pharma Inc. | Method for treating rhabdoid tumors |
WO2022221834A2 (en) * | 2021-04-12 | 2022-10-20 | Lantern Pharma Inc. | Method for treating lung cancer and non-small cell lung cancer |
KR20240073856A (en) * | 2021-07-29 | 2024-05-27 | 랜턴 파마 인코포레이티드 | Treatment of cancer using a combination of spironolactone and acylfulvene |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0565519B1 (en) * | 1989-10-03 | 1996-08-28 | The Regents Of The University Of California | Illudin analogs as anti-tumor agents |
US5439936A (en) * | 1989-10-03 | 1995-08-08 | The Regents Of The University Of California | Method of treating certain tumors using illudin analogs |
US5932553A (en) * | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
US5723632A (en) * | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
JP4989648B2 (en) * | 2005-08-03 | 2012-08-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Iludine analogues useful as anticancer agents |
US10285955B2 (en) * | 2014-04-10 | 2019-05-14 | Af Chemicals, Llc | Affinity medicant conjugate |
CN106458922A (en) * | 2014-04-10 | 2017-02-22 | Af化学药品有限责任公司 | Affinity medicant conjugates |
US9725769B1 (en) * | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
US20210230662A1 (en) * | 2018-10-14 | 2021-07-29 | Lantern Pharma Inc. | Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers |
-
2019
- 2019-09-04 EP EP19858324.7A patent/EP3846791A4/en active Pending
- 2019-09-04 JP JP2021513267A patent/JP7489966B2/en active Active
- 2019-09-04 CN CN201980064460.1A patent/CN112804995A/en active Pending
- 2019-09-04 KR KR1020217009945A patent/KR20210087435A/en active Search and Examination
- 2019-09-04 CA CA3111772A patent/CA3111772A1/en active Pending
- 2019-09-04 AU AU2019335222A patent/AU2019335222A1/en active Pending
- 2019-09-04 MX MX2021002529A patent/MX2021002529A/en unknown
- 2019-09-04 BR BR112021006710-8A patent/BR112021006710A2/en not_active Application Discontinuation
- 2019-09-04 WO PCT/US2019/049555 patent/WO2020051222A1/en unknown
-
2021
- 2021-03-04 US US17/192,838 patent/US11739043B2/en active Active
-
2023
- 2023-08-27 US US18/238,512 patent/US20230399285A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021006710A2 (en) | 2021-08-10 |
CN112804995A (en) | 2021-05-14 |
CA3111772A1 (en) | 2020-03-12 |
MX2021002529A (en) | 2021-08-11 |
EP3846791A4 (en) | 2022-06-08 |
JP7489966B2 (en) | 2024-05-24 |
EP3846791A1 (en) | 2021-07-14 |
US20210198191A1 (en) | 2021-07-01 |
JP2021536492A (en) | 2021-12-27 |
AU2019335222A1 (en) | 2021-05-06 |
WO2020051222A1 (en) | 2020-03-12 |
KR20210087435A (en) | 2021-07-12 |
US11739043B2 (en) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230399285A1 (en) | Illudin analogs, uses thereof, and methods for synthesizing the same | |
EP0125702B1 (en) | Polycyclic aromatic compounds | |
JP3045017B2 (en) | Stilbene derivatives and anticancer agents containing the same | |
US7285683B2 (en) | Bicyclic and tricyclic cannabinoids | |
US20080234229A1 (en) | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | |
US6235736B1 (en) | 3-anilino-2-cycloalkenone derivatives | |
US7589239B2 (en) | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | |
US7531695B2 (en) | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | |
CZ297803B6 (en) | Illudin analogs and pharmaceutical composition containing thereof | |
JP5972911B2 (en) | Method for the synthesis of molybdopterin precursor Z derivatives | |
US7468462B2 (en) | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | |
US9598393B2 (en) | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | |
US7572816B2 (en) | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | |
US4912100A (en) | Platinum complex, process for preparing same and antitumor agent | |
US9428493B2 (en) | Schweinfurthin analogues | |
US8637685B2 (en) | Schweinfurthin analogues | |
JPH0570448A (en) | Hiv protease inhibitor | |
US7109242B2 (en) | Carboxylic compound and medicine comprising the same | |
US8461371B2 (en) | Method of enantioselective addition to imines | |
US20230233589A1 (en) | Methods for treating cancer using a modified monosaccharide compound | |
EP1556387B1 (en) | Substituted benzol e| 1,4| oxazino 3,2-g| isoindole derivatives, method for preparing same and pharmaceutical compositions containing same | |
LU83547A1 (en) | HETEROPROSTAGLANDIN DERIVATIVES AND THEIR PREPARATION METHODS | |
FR2568878A1 (en) | NOVEL (PHENYLPIPERAZINYLETHYLAMINE ETHOXY) -4-PHENOL DERIVATIVES, THEIR PREPARATION METHOD AND THEIR THERAPEUTIC APPLICATION | |
JPH0745475B2 (en) | Heteropolycyclic compound | |
JPS6393783A (en) | Isoquinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |